Revolution Medicines (RVMDW) Financials

Revolution Medicines remains a development-stage biotech with substantial financial resources, but its operating losses and cash burn are accelerating. The company reported no revenue in Q2 2026, continuing a period of minimal or nonexistent commercial revenue since Q3 2024. Its financial profile therefore remains driven primarily by research progress, financing activity and the value of its drug pipeline rather than sales.

• Liquidity has strengthened considerably. Cash and equivalents plus short-term investments totaled approximately $3.94 billion at June 30, 2026, up from roughly $1.87 billion at the end of Q2 2025 and $1.55 billion at the end of Q3 2024.
• The balance sheet has a strong current-asset position. Total current assets of $4.03 billion compared with current liabilities of $354.1 million, representing a current ratio of approximately 11.4 times.
• Recent financing materially extended the company’s capital base. Revolution Medicines raised approximately $1.69 billion from common-equity issuance in Q2 2026, contributing to a $374.5 million increase in cash and equivalents during the quarter despite operating and investing cash outflows.
• Cash resources appear capable of funding operations for multiple quarters. Q2 operating cash burn was $387.3 million, implying a simple liquidity runway of roughly 10 quarters based on cash and short-term investments alone. Actual runway will depend on clinical spending, investment returns, financing and potential partnerships.
• Research investment is expanding. Research and development expense rose from $134.9 million in Q2 2024 to $224.1 million in Q2 2025 and $394.9 million in Q2 2026, indicating an increasingly aggressive investment cycle for the pipeline.
• Investment activity is producing significant cash-flow volatility. The company purchased $2.04 billion of investments and sold or received maturities of $382.0 million in Q2 2026, resulting in $1.66 billion of investing cash outflow. These transactions largely reflect management of its liquid securities portfolio rather than conventional capital expenditures.
• Debt has become a more visible balance-sheet item. Long-term debt was $487.4 million in Q2 2026, while total liabilities increased to $1.72 billion from $564.2 million in Q2 2025. Equity still represented approximately 60% of total assets, but the liability increase warrants monitoring.
• Operating losses are widening sharply. Net loss increased from $133.2 million in Q2 2024 to $247.8 million in Q2 2025 and $644.4 million in Q2 2026. The Q2 2026 loss was also substantially larger than the $453.8 million loss recorded in Q1 2026.
• Operating expenses are rising faster than the company’s financial resources can be replenished organically. Total operating expenses climbed from $156.6 million in Q2 2024 to $264.7 million in Q2 2025 and $505.1 million in Q2 2026. Selling, general and administrative expense also increased to $110.2 million from $40.6 million over the same period.
• Shareholder dilution is a continuing risk. Weighted-average basic shares outstanding increased from 165.1 million in Q2 2024 to 188.6 million in Q2 2025 and 210.9 million in Q2 2026. The large equity raise improved liquidity but reduced each existing shareholder’s ownership percentage.

Overall, Revolution Medicines has moved from a relatively small cash-rich biotech to a much larger, better-funded company with approximately $4 billion in cash and short-term investments. However, the company is consuming cash at an accelerating rate, has not established recurring revenue and continues to rely on equity financing. For investors, the key questions are whether increased research spending produces successful clinical outcomes and eventual commercialization before additional dilution becomes necessary.